Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Top Cited Papers
- 24 January 2019
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 393 (10174), 889-898
- https://doi.org/10.1016/s0140-6736(19)30036-4
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 studyThe Lancet Infectious Diseases, 2018
- Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman PrimatesThe Journal of Infectious Diseases, 2018
- Structural and molecular basis for Ebola virus neutralization by protective human antibodiesScience, 2016
- Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family FiloviridaeArchiv für die gesamte Virusforschung, 2012
- Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal AntibodiesScience Translational Medicine, 2012
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences, 2012
- Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common ReceptorJournal of Biological Chemistry, 2006
- Exotic emerging viral diseases: progress and challengesNature Medicine, 2004
- Global Aspects of Emerging and Potential Zoonoses: a WHO PerspectiveEmerging Infectious Diseases, 1997
- Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989–1990 U.S. epizooticPublished by Springer Nature ,1996